scholarly journals Comprehensive Meta-Analysis of COVID-19 Global Metabolomics Datasets

Metabolites ◽  
2021 ◽  
Vol 11 (1) ◽  
pp. 44
Author(s):  
Zhiqiang Pang ◽  
Guangyan Zhou ◽  
Jasmine Chong ◽  
Jianguo Xia
Keyword(s):  
Disease Progression ◽  
Meta Analysis ◽  
Clinical Care ◽  
Visual Data Mining ◽  
Global Pandemic ◽  
Clinical Presentations ◽  
Spectra Processing ◽  
Global Metabolomics ◽  
Novel Coronavirus ◽  
Meta Analyses

The novel coronavirus SARS-CoV-2 has spread across the world since 2019, causing a global pandemic. The pathogenesis of the viral infection and the associated clinical presentations depend primarily on host factors such as age and immunity, rather than the viral load or its genetic variations. A growing number of omics studies have been conducted to characterize the host immune and metabolic responses underlying the disease progression. Meta-analyses of these datasets have great potential to identify robust molecular signatures to inform clinical care and to facilitate therapeutics development. In this study, we performed a comprehensive meta-analysis of publicly available global metabolomics datasets obtained from three countries (United States, China and Brazil). To overcome high heterogeneity inherent in these datasets, we have (a) implemented a computational pipeline to perform consistent raw spectra processing; (b) conducted meta-analyses at pathway levels instead of individual feature levels; and (c) performed visual data mining on consistent patterns of change between disease severities for individual studies. Our analyses have yielded several key metabolic signatures characterizing disease progression and clinical outcomes. Their biological interpretations were discussed within the context of the current literature. To the best of our knowledge, this is the first comprehensive meta-analysis of global metabolomics datasets of COVID-19.

scholarly journals Negative pressure rooms and COVID-19

2020 ◽  
Vol 31 (1-2) ◽  
pp. 18-23
Author(s):  
Sammy Al-Benna
Keyword(s):  
Negative Pressure ◽  
Health Care Professionals ◽  
Healthcare Professionals ◽  
Clinical Care ◽  
Public Health Emergency ◽  
Positive Pressure ◽  
Global Pandemic ◽  
Operating Theatres ◽  
Novel Coronavirus ◽  
Surrounding Areas

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes 2019 novel coronavirus disease (COVID-19), has rapidly developed into a global pandemic and public health emergency. The transmission and virulence of this new pathogen have raised concern for how best to protect healthcare professionals while effectively providing care to the infected patient requiring surgery. Although negative pressure rooms are ideal for aerosol-generating procedures, such as intubation and extubation, most operating theatres are generally maintained at a positive pressure when compared with the surrounding areas. This article compares negative and positive pressure rooms and the advantages of a negative pressure environment in optimising clinical care and minimising the exposure of patients and health care professionals to SARS-CoV-2.

scholarly journals Challenges and Opportunities from Targeting Inflammatory Responses to SARS-CoV-2 Infection: A Narrative Review

2020 ◽  
Vol 9 (12) ◽  
pp. 4021
Author(s):  
Vincenzo Lariccia ◽  
Simona Magi ◽  
Tiziano Serfilippi ◽  
Marwa Toujani ◽  
Santo Gratteri ◽  
...  
Keyword(s):  
Inflammatory Responses ◽  
Early Stage ◽  
Clinical Care ◽  
Current Evidence ◽  
Global Pandemic ◽  
Challenges And Opportunities ◽  
Inflammatory Processes ◽  
Inflammatory Drugs ◽  
Anti Inflammatory ◽  
Novel Coronavirus

The novel coronavirus disease 2019 (COVID-19) is a global pandemic that continues to sweep across the world, posing an urgent need for effective therapies and prevention of the spread of the severe acute respiratory syndrome related to coronavirus-2 (SARS-CoV-2). A major hypothesis that is currently guiding research and clinical care posits that an excessive and uncontrolled surge of pro-inflammatory cytokines (the so-called “cytokine storm”) drives morbidity and mortality in the most severe cases. In the overall efforts made to develop effective and safe therapies (including vaccines) for COVID-19, clinicians are thus repurposing ready-to-use drugs with direct or indirect anti-inflammatory and immunomodulatory activities. Speculatively, there are many opportunities and challenges in targeting immune/inflammatory processes in the evolving settings of COVID-19 disease because of the need to safely balance the fight against virus and aggressive inflammation versus the suppression of host immune defenses and the risk of additional harms in already compromised patients. To this end, many studies are globally underway to weigh the pros and cons of tailoring drugs used for inflammatory-driven conditions to COVID-19 patient care, and the next step will be to summarize the growing clinical trial experience into clean clinical practice. Based on the current evidence, anti-inflammatory drugs should be considered as complementary approaches to anti-viral drugs that need to be timely introduced in the management of COVID-19 according to disease severity. While drugs that target SARS-CoV-2 entry or replication are expected to confer the greatest benefits at the early stage of the infection, anti-inflammatory drugs would be more effective in limiting the inflammatory processes that drive the worsening of the disease.

scholarly journals Prognostic value of miR-21 for prostate cancer: a systematic review and meta-analysis

2021 ◽  
Author(s):  
MY Cynthia Stafford ◽  
Colin E Willoughby ◽  
Colum P Walsh ◽  
Declan J McKenna
Keyword(s):  
Prostate Cancer ◽  
Systematic Review ◽  
Disease Progression ◽  
Poor Prognosis ◽  
Meta Analysis ◽  
Risk Groups ◽  
Cochrane Library ◽  
Clinical Biomarker ◽  
Meta Analyses ◽  
The Relationship

Elevated levels of miR-21 expression are associated with many cancers, suggesting it may be a promising clinical biomarker. In prostate cancer (PCa), however, there is still no consensus about the usefulness of miR-21 as an indicator of disease progression. This systematic review and meta-analysis was conducted to investigate the value of miR-21 expression as a prognostic measurement in PCa patients. Medline (Ovid), EMBASE, Web of Science, Scopus and Cochrane Library databases were systematically searched for relevant publications between 2010 to 2021. Studies exploring the relationship between miR-21 expression, PCa prognosis and clinicopathological factors were selected for review. Those reporting hazard ratio (HR) and 95% confidence intervals (CIs) were subject to meta-analyses. Fixed-effect models were employed to calculated pooled HRs and 95% CIs. Risk of bias in each study was assessed using QUIPS tool. Certainty of evidence in each meta-analysis was assessed using GRADE guidelines. A total of 64 studies were included in the systematic review. Of these, 11 were eligible for inclusion in meta-analysis. Meta-analyses revealed that high miR-21 expression was associated with poor prognosis: HR=1.58 (95% CI=1.19-2.09) for biochemical recurrence, MODERATE certainty; HR=1.46 (95% CI=1.06-2.01) for death, VERY LOW certainty; and HR=1.26 (95% CI=0.70-2.27) for disease progression, VERY LOW certainty. Qualitative summary revealed elevated miR-21 expression was significantly positively associated with PCa stage, Gleason score and risk groups. This systematic review and meta-analysis suggests that elevated levels of miR-21 are associated with poor prognosis in PCa patients. miR-21 expression may therefore be a useful prognostic biomarker in this disease.

scholarly journals COVID-19 Associated Multisystem Inflammatory Syndrome: A Systematic Review and Meta-analysis

2020 ◽  
Author(s):  
Ashkan Baradaran ◽  
Abdolreza Malek ◽  
Nasrin Moazzen ◽  
Zahra Abbasi Shaye
Keyword(s):  
Systematic Review ◽  
Meta Analysis ◽  
Gastrointestinal Symptoms ◽  
Multiple Organ ◽  
Current Evidence ◽  
Cardiac Complications ◽  
Clinical Presentations ◽  
Atypical Kawasaki Disease ◽  
Novel Coronavirus ◽  
Inflammatory Syndrome

The prevalence of multisystem inflammatory syndrome in children (MIS-C) has increased since the coronavirus disease 2019 (COVID-19) pandemic started. This study was aimed to describe clinical manifestation and outcomes of MIS-C associated with COVID-19. This systematic review and meta-analysis were conducted on all available literature until July 3rd, 2020. The screening was done by using the following keywords: (“novel coronavirus” Or COVID-19 or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or coronavirus) and ("MIS-C" or "multisystem inflammatory" or Kawasaki). Data on gender, ethnicity, clinical presentations, need for mechanical ventilation or admission to intensive care unit (ICU), imaging, cardiac complications, and COVID-19 laboratory results were extracted to measure the pooled estimates. Out of 314 found articles, 16 articles with a total of 600 patients were included in the study, the most common presentation was fever (97%), followed by gastrointestinal symptoms (80%), and skin rashes (60%) as well as shock (55%), conjunctivitis (54%), and respiratory symptoms (39%). Less common presentations were neurologic problems (33%), and skin desquamation (30%), MIS-C was slightly more prevalent in males (53.7%) compared to females (46.3%). The findings of this meta-analysis on current evidence found that the common clinical presentations of COVID-19 associated MIS-C include a combination of fever and mucocutaneous involvements, similar to atypical Kawasaki disease, and multiple organ dysfunction. Due to the relatively higher morbidity and mortality rate, it is very important to diagnose this condition promptly.  

scholarly journals The Role of Machine Learning Techniques to Tackle COVID-19 Crisis: A Systematic Review.

2020 ◽  
Author(s):  
Hafsa Bareen Syeda ◽  
Mahanazuddin Syed ◽  
Kevin Wayne Sexton ◽  
Shorabuddin Syed ◽  
Salma Begum ◽  
...  
Keyword(s):  
Machine Learning ◽  
Systematic Review ◽  
Disease Progression ◽  
Meta Analysis ◽  
Machine Learning Techniques ◽  
Data Types ◽  
Detection And Diagnosis ◽  
Novel Coronavirus ◽  
The Impact

Background: The novel coronavirus responsible for COVID-19 has caused havoc with patients presenting a spectrum of complications forcing the healthcare experts around the globe to explore new technological solutions, and treatment plans. Machine learning (ML) based technologies have played a substantial role in solving complex problems, and several organizations have been swift to adopt and customize them in response to the challenges posed by the COVID-19 pandemic. Objective: The objective of this study is to conduct a systematic literature review on the role of ML as a comprehensive and decisive technology to fight the COVID-19 crisis in the arena of epidemiology, diagnosis, and disease progression. Methods: A systematic search in PubMed, Web of Science, and CINAHL databases was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guidelines to identify all potentially relevant studies published and made available between December 1, 2019, and June 27, 2020. The search syntax was built using keywords specific to COVID-19 and ML. A total of 128 qualified articles were reviewed and analyzed based on the study objectives. Results: The 128 publications selected were classified into three themes based on ML applications employed to combat the COVID-19 crisis: Computational Epidemiology (CE), Early Detection and Diagnosis (EDD), and Disease Progression (DP). Of the 128 studies, 70 focused on predicting the outbreak, the impact of containment policies, and potential drug discoveries, which were grouped into the CE theme. For the EDD, we grouped forty studies that applied ML techniques to detect the presence of COVID-19 using the patient's radiological images or lab results. Eighteen publications that focused on predicting the disease progression, outcomes (recovery and mortality), Length of Stay (LOS), and number of Intensive Care Unit (ICU) days for COVID-19 positive patients were classified under the DP theme. Conclusions: In this systematic review, we assembled the current COVID-19 literature that utilized ML methods to provide insights into the COVID-19 themes, highlighting the important variables, data types, and available COVID-19 resources that can assist in facilitating clinical and translational research.

scholarly journals Association of Body Mass Index with Clinical Outcomes in Non-Dialysis-Dependent Chronic Kidney Disease: A Systematic Review and Meta-Analysis

2015 ◽  
Vol 6 (1) ◽  
pp. 37-49 ◽  
Author(s):  
Seyed-Foad Ahmadi ◽  
Golara Zahmatkesh ◽  
Emad Ahmadi ◽  
Elani Streja ◽  
Connie M. Rhee ◽  
...  
Keyword(s):  
Systematic Review ◽  
Body Mass Index ◽  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Disease Progression ◽  
Body Mass ◽  
Meta Analysis ◽  
Risk Of Death ◽  
Kidney Disease Progression ◽  
Meta Analyses

Background: Previous studies have not shown a consistent link between body mass index (BMI) and outcomes such as mortality and kidney disease progression in non-dialysis-dependent chronic kidney disease (CKD) patients. Therefore, we aimed to complete a systematic review and meta-analysis study on this subject. Methods: We searched MEDLINE, EMBASE, Web of Science, Cumulative Index to Nursing and Allied Health Literature (CINAHL), and Cochrane Central Register of Controlled Trials (CENTRAL), and screened 7,123 retrieved studies for inclusion. Two investigators independently selected the studies using predefined criteria and assessed each study's quality using the Newcastle-Ottawa quality assessment scale. We meta-analyzed the results based on the BMI classification system by the WHO. Results: We included 10 studies (with a total sample size of 484,906) in the systematic review and 4 studies in the meta-analyses. The study results were generally heterogeneous. However, following reanalysis of the largest reported study and our meta-analyses, we observed that in stage 3-5 CKD, being underweight was associated with a higher risk of death while being overweight or obese class I was associated with a lower risk of death; however, obesity classes II and III were not associated with risk of death. In addition, reanalysis of the largest available study showed that a higher BMI was associated with an incrementally higher risk of kidney disease progression; however, this association was attenuated in our pooled results. For earlier stages of CKD, we could not complete meta-analyses as the studies were sparse and had heterogeneous BMI classifications and/or referent BMI groups. Conclusion: Among the group of patients with stage 3-5 CKD, we found a differential association between obesity classes I-III and mortality compared to the general population, indicating an obesity paradox in the CKD population.

scholarly journals COVID-19 and Venous Thromboembolism: A Meta-analysis of Literature Studies

2020 ◽  
Vol 46 (07) ◽  
pp. 763-771 ◽  
Author(s):  
Alessandro Di Minno ◽  
Pasquale Ambrosino ◽  
Ilenia Calcaterra ◽  
Matteo Nicola Dario Di Minno
Keyword(s):  
Venous Thromboembolism ◽  
Wide Spectrum ◽  
Meta Analysis ◽  
Z Score ◽  
Thromboembolic Complications ◽  
Vein Thrombosis ◽  
Clinical Presentations ◽  
Meta Analyses ◽  
Detailed Search ◽  
Deep Vein

AbstractCoronavirus disease 2019 (COVID-19) may have a wide spectrum of clinical presentations, leading in some cases to a critical condition with poor long-term outcomes and residual disability requiring post-acute rehabilitation. A major concern in severe COVID-19 is represented by a concomitant prothrombotic state. However, contrasting data are available about the prevalence of venous thromboembolism (VTE), including deep vein thrombosis (DVT) and/or pulmonary embolism (PE). A detailed search on the association of COVID-19 with thromboembolic complications was conducted in the main electronic databases (PubMed, Web of Science, and Scopus) according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The weighted mean prevalence (WMP) with 95% confidence interval (95% CI) was calculated with the random-effects model. Twenty studies enrolling 1,988 COVID-19 patients were included. The WMP of VTE was 31.3% (95% CI: 24.3–39.2%). The WMP of DVT was 19.8% (95% CI: 10.5–34.0%), whereas the WMP of PE was 18.9% (95% CI: 14.4–24.3%). Similar results were obtained when specifically analyzing studies on patients admitted to intensive care units and those on patients under antithrombotic prophylaxis. Regression models showed that an increasing age was associated with a higher prevalence of VTE (Z-score: 3.11, p = 0.001), DVT (Z-score: 2.33, p = 0.002), and PE (Z-score: 3.03, p = 0.002), while an increasing body mass index was associated with an increasing prevalence of PE (Z-score = 2.01, p = 0.04). Male sex did not impact the evaluated outcomes. The rate of thromboembolic complications in COVID-19 patients is definitely high. Considering the risk of fatal and disabling complications, adequate screening procedures and antithrombotic strategies should be implemented.

scholarly journals The Negative Impact of Obesity on the Occurrence and Prognosis of the 2019 Novel Coronavirus (COVID-19) Disease: A Systematic Review and Meta-Analysis

2020 ◽  
Author(s):  
Tahereh Raeisi ◽  
Hadis Mozaffari ◽  
Nazaninzahra Sepehri ◽  
Mohammad Alizadeh ◽  
Mina Darand ◽  
...  
Keyword(s):  
Intensive Care Unit ◽  
Mechanical Ventilation ◽  
Risk Factor ◽  
Intensive Care ◽  
Clinical Outcomes ◽  
Meta Analysis ◽  
Clinical Care ◽  
Icu Admission ◽  
Prevalence Of Obesity ◽  
Novel Coronavirus

Abstract Background: the 2019 novel coronavirus (COVID-19) is an emerging pandemic, with a disease course varying from asymptomatic infection to critical disease resulting to death. Recognition of prognostic factors is essential because of its growing prevalence and high clinical costs. This meta-analysis aimed to evaluate the global prevalence of obesity in COVID-19 patients and to investigate whether obesity is a risk factor for the COVID-19, COVID-19 severity, and its poor clinical outcomes including hospitalization, intensive care unit (ICU) admission, need for mechanical ventilation, and mortality.Methods: The study protocol was registered on to PROSPERO (CRD42020203386). A systematic search of Scopus, Medline, and Web of Sciences was conducted on June 2020, to find pertinent studies. After selection, 54 studies from 10 different countries were included in the quantitative analyses. Pooled odds ratios (OR) with 95% confidence intervals (CIs) were calculated to assess the associations. Results: The prevalence of obesity was 33% (95% CI, 30.0%–35.0%) among patients with COVID-19. Obesity was significantly associated with susceptibility to COVID-19 (OR=2.42, 95% CI: 1.58 to 3.70; moderate certainty) and COVID-19 severity (OR=1.62, 95% CI: 1.48 to 1.76; low certainty). Furthermore, obesity was a significant risk factor for hospitalization (OR=1.75, 95% CI: 1.47 to 2.09; very low certainty), mechanical ventilation (OR=2.24, 95% CI: 1.70 to 2.94; low certainty), intensive care unit (ICU) admission (OR=1.75, 95% CI: 1.38 to 2.22; low certainty), and death (OR=1.23, 95% CI: 1.06 to 1.41; low certainty) in COVID-19 patients. In the subgroup analyses, these associations were supported by the majority of subgroups. Conclusions: Obesity is associated with COVID-19 and its poor clinical outcomes. Thus, it is highly recommended to consider obesity status in prognostic scores and improvement of guidelines for the clinical care of patients with COVID-19.

scholarly journals Clinical Laboratory Parameters Associated with Severe or Critical Novel Coronavirus Disease 2019 (COVID-19): A Systematic Review and Meta-analysis

2020 ◽  
Author(s):  
Jude Moutchia ◽  
Pratik Pokharel ◽  
Aldiona Kerri ◽  
Kaodi McGaw ◽  
Shreeshti Uchai ◽  
...  
Keyword(s):  
Immune Response ◽  
Troponin I ◽  
Clinical Laboratory ◽  
Data Extraction ◽  
Meta Analysis ◽  
Adaptive Immune Response ◽  
Laboratory Parameters ◽  
Reactive Protein ◽  
Novel Coronavirus ◽  
Meta Analyses

AbstractBackgroundTo date, several clinical laboratory parameters associated with COVID-19 severity have been reported. However, these parameters have not been observed consistently across studies. The aim of this review was to assess clinical laboratory parameters which may serve as markers or predictors of severe or critical COVID-19 diseaseMethodsWe conducted a systematic search of MEDLINE, Embase, Web of Science, CINAHL and Google Scholar databases from 2019 through April 18, 2020, and reviewed bibliographies of eligible studies, relevant systematic reviews, and the medRxiv pre-print server. We included hospital-based observational studies reporting clinical laboratory parameters of confirmed cases of COVID-19 and excluded studies having large proportions (>10%) of children and pregnant women. Two authors independently carried out screening of articles, data extraction and quality assessment. Meta-analyses were done using random effects model. Meta-median difference (MMD) and 95% confidence interval (CI) was calculated for each laboratory parameter.ResultsForty-five studies in 6 countries were included. Compared to non-severe COVID-19 cases, severe or critical COVID-19 disease was characterised by higher neutrophil count (MMD: 1.23 [95% CI: 0.58 to 1.88] ×109 cells/L), and lower lymphocyte and CD4 counts with MMD (95% CI) of -0.39 (-0.47, -0.31) ×109 cells/L and -204.9 (-302.6, -107.1) cells/μl, respectively. Other notable results were observed for C-reactive protein (MMD: 36.97 [95% CI: 27.58, 46.35] mg/L), interleukin-6 (MMD: 17.37 [95% CI: 4.74, 30.00] pg/ml,), Troponin I (MMD: 0.01 [0.00, 0.02] ng/ml), and D-dimer (MMD: 0.65 [0.45, 0.85] mg/ml).Conclusions and RelevanceRelative to non-severe COVID-19, severe or critical COVID-19 is characterised by increased markers of innate immune response, decreased markers of adaptive immune response, and increased markers of tissue damage and major organ failure. These markers could be used to recognise severe or critical disease and to monitor clinical course of COVID-19.

scholarly journals Do prostatectomy suitable for localized prostate cancer patient: evidence from meta-analysis

2019 ◽  
Author(s):  
Xiaojin Luo ◽  
Meilian Yi ◽  
Qun Hu ◽  
Weihua Yin
Keyword(s):  
Prostate Cancer ◽  
Cancer Patient ◽  
Disease Progression ◽  
Prostate Cancer Patient ◽  
Evidence Synthesis ◽  
Meta Analysis ◽  
Localized Prostate Cancer ◽  
Risk Of Death ◽  
Significant Difference ◽  
Meta Analyses

Abstract Objective:To evaluate the role of prostatectomy for localized prostate cancer patient. Methods: A systematic search was conducted using PubMed, and Web of Science through March 22, 2019 according to Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines to identify studies reporting on prostatectomy for localized prostate cancer patient. Results: Of a total of 1827 studies, 6 were considered for evidence synthesis. A total of 4476 patients in 4 studies were included for survival analysis, 2,779 patients received prostatectomy and 1,697 patients were received no treatment but regularly followed up. Two other studies were included for adverse effects analysis. Prostatectomy displayed a significantly decreased risk of death of 35% compared with observation (OR=0.65, 95%CI 0.53-0.81, P<0.0001). Pooled data indicated prostatectomy reduced 55% risk of disease progression (OR=0.45, 95% CI 0.34-0.60, P<0.00001). Anxiety, depressed mode, wellbeing, and sense of meaningfulness for patients were no difference between prostatectomy and observation group. However, prostatectomy increased 2.77 folds risk of erection dysfunction (OR=2.77, 95% CI, 1.60–4.81, P=0.0003 Conclusion: Prostatectomy prolonged survival and deferred disease progression compared to observation for localized prostate cancer patients. Symptoms between two groups were not significant difference except for erection function. Patients should decide prostatectomy or not after balancing the survival benefit and erection dysfunction.

Sign in / Sign up

Export Citation Format

Share Document